Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT

被引：50

作者：

Parida, Girish Kumar ^{[1
]}

Tripathy, Sarthak ^{[1
]}

Gupta, Shreya Datta ^{[1
]}

Singhal, Abhinav ^{[1
]}

Kumar, Rakesh ^{[1
]}

Bal, Chandrasekhar ^{[1
]}

Shamim, Shamim Ahmed ^{[1
]}

机构：

[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India

来源：

CLINICAL NUCLEAR MEDICINE | 2018年 / 43卷 / 04期

关键词：

neuroendocrine tumor; prostate malignancy; FDG PET/CT; DOTANOC PET/CT; PSMA PET/CT; POSITRON-EMISSION-TOMOGRAPHY; CANCER;

D O I：

10.1097/RLU.0000000000002013

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Ga-68-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-68-DOTANOC PET/CT and F-18-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-68-PSMA PET/CT imaging and benefit of Ga-68-DOTANOC PET/CT and F-18-FDG PET/CT in such cases.

引用

页码：248 / 249

页数：2

共 9 条

[1] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[2] 68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation [J].

Chen, Sirong ;

Cheung, Shing Kee ;

Wong, Ka-nin ;

Wong, Kwok Kee ;

Ho, Chi-lai .

CLINICAL NUCLEAR MEDICINE, 2016, 41 (12) :959-960

[3] Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose [J].

Effert, PJ ;

Bares, R ;

Handt, S ;

Wolff, JM ;

Bull, U ;

Jakse, G .

JOURNAL OF UROLOGY, 1996, 155 (03) :994-998

[4] Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? [J].

Grigore, Alexandru Dan ;

Ben-Jacob, Eshel ;

Farach-Carson, Mary C. .

FRONTIERS IN ONCOLOGY, 2015, 5

[5] Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy [J].

Hofer, C ;

Laubenbacher, C ;

Block, T ;

Breul, J ;

Hartung, R ;

Schwaiger, M .

EUROPEAN UROLOGY, 1999, 36 (01) :31-35

[6] FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate [J].

Liu, Yiyan .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2008, 6 (1)

[7] Molecular positron emission tomography and PET/CT imaging in urological malignancies [J].

Powles, Torn ;

Murray, Iain ;

Brock, Cathryn ;

Oliver, Tim ;

Avril, Norbert .

EUROPEAN UROLOGY, 2007, 51 (06) :1511-1521

[8] The many faces of neuroendocrine differentiation in prostate cancer progression [J].

Terry, Stephane ;

Beltran, Himisha .

FRONTIERS IN ONCOLOGY, 2014, 4

[9] Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT [J].

Usmani, Sharjeel ;

Ahmed, Najeeb ;

Marafi, Fahad ;

Rasheed, Rashid ;

Amanguno, Henney G. ;

al Kandari, Fareeda .

CLINICAL NUCLEAR MEDICINE, 2017, 42 (05) :410-413

← 1 →